首页> 外国专利> MUTATIONS IN HUMAN PCSK9 GENES ASSOCIATED WITH HYPERCHOLESTEROLEMIA

MUTATIONS IN HUMAN PCSK9 GENES ASSOCIATED WITH HYPERCHOLESTEROLEMIA

机译:高胆固醇血症与人PCSK9基因的突变

摘要

An isolated or recombinant PCSK9 gene or its fragment and/or an isolated or purified Neural Apoptosis Regulated Convertase 1 (NARC-1) protein or its fragment comprising alterations, is new. An isolated or recombinant PCSK9 gene or its fragment comprising an alteration, where the alteration is a substitution at nucleotide 625 and/or 890 of a sequence comprising 3617 bp (SEQ ID NO: 1) fully defined in the specification, or selected from polymorphisms given in the specification, and/or an isolated or purified NARC-1 protein or its fragment comprising an alteration, where the alteration is an insertion of a residue Leucine at position 15 of a sequence comprising 692 amino acids (SEQ ID NO: 2) fully defined in the specification, a substitution of the residue Arginine at position 46 of SEQ ID NO: 2 by a Leucine, a substitution of the residue Alanine at position 53 of SEQ ID NO: 2 by a Valine, a substitution of the residue Serine at position 127 of SEQ ID NO: 2 by an Arginine, a substitution of the residue Phenylalanine at position 216 of SEQ ID NO: 2 by a Leucine, a substitution of the residue isoleucine at position 474 of SEQ ID NO: 2 by a Valine, a substitution of the residue Glutamic acid at position 670 of SEQ ID NO: 2 by a Glycine or their combination. Independent claims are also included for: (1) a method of genotyping at least one polymorphism; (2) a method of detecting the presence of or predisposition to hypercholesterolemia, more particularly autosomal dominant hypercholesterolemia (ADH), lipid and lipoprotein metabolism disorders, atherosclerosis, or cardiovascular disease (CVD) in a subject; (3) a method of selecting biologically active compounds; and (4) a diagnostic kit comprising primers, probes and/or antibodies for detecting in a sample from a subject the presence of an alteration in the PCSK9 gene or in the NARC-1 protein. ACTIVITY : Antilipemic; Antiarteriosclerotic; Cardiovascular-Gen. No biological data given. MECHANISM OF ACTION : NARC-Modulator-1; Gene therapy.
机译:分离的或重组的PCSK9基因或其片段和/或分离的或纯化的神经细胞凋亡调节的转化酶1(NARC-1)蛋白或其包含改变的片段是新的。包含改变的分离或重组PCSK9基因或其片段,其中所述改变是说明书中完全定义或选自给定多态性的包含3617 bp(SEQ ID NO:1)的序列在核苷酸625和/或890处的取代在说明书中,和/或分离的或纯化的NARC-1蛋白或其片段,其包含改变,其中所述改变是残基亮氨酸完全插入包含692个氨基酸(SEQ ID NO:2)的序列的15位如说明书中定义的,用亮氨酸取代SEQ ID NO:2的第46位残基精氨酸,用缬氨酸取代SEQ ID NO:2的第53位的残基丙氨酸,取代丝氨酸。 SEQ ID NO:2的127位被精氨酸取代,SEQ ID NO:2的216位残基苯丙氨酸被亮氨酸取代,SEQ ID NO:2的474位残基异亮氨酸被缬氨酸取代,残基的取代甘氨酸或其组合在SEQ ID NO:2的670位的谷氨酸。还包括以下方面的独立权利要求:(1)对至少一种多态性进行基因分型的方法; (2)一种检测受试者中高胆固醇血症,特别是常染色体显性高胆固醇血症(ADH),脂质和脂蛋白代谢紊乱,动脉粥样硬化或心血管疾病(CVD)的存在或易感性的方法; (3)选择生物活性化合物的方法; (4)诊断试剂盒,其包含用于检测来自受试者的样品中PCSK9基因或NARC-1蛋白中是否存在改变的引物,探针和/或抗体。活动:抗血脂;抗动脉硬化;心血管基因没有给出生物学数据。作用机理:NARC-Modulator-1;基因治疗。

著录项

  • 公开/公告号DE602004010384T2

    专利类型

  • 公开/公告日2008-11-13

    原文格式PDF

  • 申请/专利号DE20046010384T

  • 发明设计人

    申请日2004-04-23

  • 分类号C12Q1/68;C12N9/64;C12N15/57;A61K38/48;A61P3/06;

  • 国家 DE

  • 入库时间 2022-08-21 19:08:22

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号